


Oncardia Cardiology Imaging

Oncardia

First Functional "Hot Spot" cardiac ischemia imaging agent completing Phase 2b/3 Trials


Traditional MPI Cold Spot Imaging



Rest/Stress



Oncardia® Hot Spot Imaging



Rest Only

- First "functional hot spot" cardiac ischemia imaging agent developed for both SPECT and PET imaging
- Allows for direct hot spot imaging of cardiac ischemia with significantly improved accuracy
- Eliminates the need to stress the patient reducing overall imaging time to less than 30 minutes
- Clinical trial results to date show higher specificity and sensitivity than traditional MPI studies
- Significant improvement in patient flow and economics to prescribers /imaging center

How does Oncardia® work?

Oncardia® is a proprietary organic form of ethylenedicysteine conjugated with glucosamine. Unlike radiopharmaceuticals used with MPI, Oncardia® can target ischemia caused by CAD. Oncardia® localizes in the nucleus of the myocytes in the case of flow reduction which may cause glucose depletion. This process is sufficient to activate the hexosamine biosynthetic pathway which facilitates the mechanism that translocates Oncardia® into the nucleus of the cell. This is why Oncardia® can be used to detect viable cells in the region impacted by ischemia in the presence of a massive infarct which would ordinarily kill most of the effected myocytes.

- Cell>Point is a late stage Phase 3 biotech company specializing in the field of theranostic nuclear medicine through chelation technologies focused in cancer, cardiovascular, neuroendocrine, diabetes and ischemia-based diseases.
- Cell>Point has acquired 5 chelator technology platforms from The University of Texas M.D. Anderson Cancer Center.



- Cell>Point is completing a Phase 3 trial with ^{99m}Tc-Oncardia for imaging lung cancer and Phase 2b/3 trials for imaging cardiac ischemia.
- Cell>Point is preparing to move into Phase 1 and 2 trials for intra nuclear therapeutic Platinum-Oncardia and ¹⁷⁷Lu-Oncardia for the treatment of lung cancer and relapsed aggressive type B-cell lymphoma.

7120 E. Orchard Rd. Suite 350
Centennial, Colorado 80111
(303) 689-9693
www.cellpointweb.com

Oncardia® Phase 2b/3 Clinical Trials – Cardiology

Title of Study	A prospective, open-label, multicenter study with blinded over-reading characterizing the efficacy and safety of Tc-99m-Oncardia® in the evaluation of coronary artery disease (CAD)
Protocol Number	CP-ECDG-C3 - IND 106055
Indication	Detection of the presence, location (region) and severity of coronary artery disease
Primary Objectives	<p>(1) To compare the sensitivity and specificity of rest and stress SPECT studies Tc-99m-Oncardia® with the sensitivity and specificity of a myocardial perfusion SPECT study (Tc-99m-Sestamibi [MIBI]) for detecting the presence of coronary artery disease (CAD) as documented by invasive coronary angiography*</p> <p>(2) To determine the location of the CAD by identifying the wall of the myocardium affected by CAD; namely, anterior, inferior, septal, lateral or apex*</p> <p>(3) To determine the severity of the CAD by objectively comparing the size and intensity of the ischemic signal on rest and stress images obtained approximately 15 and 45 minutes post injection*</p> <p>*Modality of stress type for the Tc-99m-Oncardia study will be matched to stress type for the SPECT study: exercise, pharmacologic, or exercise/pharmacologic with similar exercise protocol. All matched pharmacologic studies will use regadenoson as the pharmacologic agent</p>


Imaging Software




Philips Healthcare developed Astonish software with the help of Cell>Point to optimize Tc-99m-Oncardia® images. This software is now installed on all Philips SPECT cameras and the software has been licensed to other major camera manufacturers. New “hot spot” imaging software is being developed which should further improve image quality.

Sensitivity and Specificity

Clinical trial data to date shows diagnostic accuracy averages 95% compared to 72% for MPI




Cell>Point invested significant time and capital in developing Oncardia® into an organic compound and a Simple Single Vial “Shake and Shoot” kit.



Cell>Point Moving Forward

Cell>Point is a private biotech company looking to license and or sale Oncardia in early 2021 after completion of the Phase 3 cardiology and lung cancer imaging trial. The international consulting firm A.T. Kearney, Inc. completed a detailed market analysis of Oncardia® for both the U.S. and Europe and found the agent should generate over \$1.7 Billion in annual revenues. 45% of the capital to develop Oncardia® has been provided by radiologist, oncologist and cardiologist.



In Q4 2020, the company will begin Phase 1-2 trials for its Platinum-Oncardia and 177Lu-Oncardia for the treatment of aggressive type B lymphoma and lung cancer. Imaging is key to our therapy. The image data provides key dosimetry data for doing and monitoring the therapeutic. Cell>Point is looking at various cardiac therapeutic options using the Oncardia® platform technology.

Additional Information:

For additional information please contact Terry Colip, Managing Member, at (303) 689-9693 or email terry.colip@cellpointweb.com